Skip to main content
. 2021 Jan 8;11:221. doi: 10.1038/s41598-020-80345-7

Figure 5.

Figure 5

Measurement of methylated ZNF154 fragments in plasma samples for cancer patient cases versus controls. A fragment is considered methylated if at least 1 of the 14 CpG sites measured per DREAMing amplicon is methylated. (A) Distribution of normalized methylated ZNF154 cfDNA fragments per mL of plasma from patients with late-stage (stage III–IV, n = 17, red) pancreatic, early-stage (stage I–II, n = 8, red) pancreatic, or late-stage ovarian (stage III–IV, n = 38, red) cancer, or normal controls (n = 20, blue). Data are plotted using standard box and whisker plots. (B) Receiver operating characteristic curves showing the classification performance of the normalized fraction of methylated ZNF154 cfDNA fragments per mL of plasma for the late-stage pancreatic, early-stage pancreatic, or ovarian cancer samples versus normal controls. Red circles indicate the optimal TPR and FPR combination based on the maximum positive difference between the TPR and FPR. ***p < 0.001; **p < 0.01, Wilcoxon rank sum two-sided test. AUC area under the curve, FPR false-positive rate, TPR true positive rate.